Cuba to turn cancer into manageable chronic disease

Havana, Feb 15 (IANS) Cuba’s biotechnological industry is developing a long-term strategy to turn cancer into a manageable chronic disease, health experts have said.

The island country currently has 28 medical products registered or in various stages of experimentation for the treatment of cancer, including therapeutic vaccines, monoclonal antibodies, interferons and peptides, Xinhua reported.

These drugs should have an increasing long-term impact in turning advanced cancer into a manageable chronic condition with an acceptable quality of life, Rolando Perez Rodriguez of the Centre of Molecular Immunology said earlier this week.

The country is preparing a package of bills to introduce new medical products in 2017, according to Rodriguez.

These products are currently in different stages of clinical trials or pre-clinical development, and should soon move toward registration and medical use.

Pedro Pablo Guerra, a specialist of the National Coordinating Centre for Clinical Trials, said the CimaVax-EGF vaccine, proved to help increase life expectancies by seven years for advanced lung cancer patients, is now being tested in four cities in Cuba.

Registered in 2008, CimaVax-EGF has since been tested on 81,000 patients and will now be used in primary health care units in Cuba.

Tested on over 300 patients, a vaccine named Heber Provac against advanced prostate cancer is currently in its third trial phase.

In this new phase, experts will compare the effectiveness of this product with Zoladex, an international therapy used to fight prostate cancer and breast cancer.

Health authorities also plan to introduce advanced imaging equipment in the fields of nuclear medicine and oncology, which will make it easier to apply more effective treatment against malignant cells, said Rodriguez.

Cancer is the second main cause of death in Cuba with about 40,000 new cases diagnosed each year, according to official statistics.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of or any employee thereof. is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here